400 results
8-K
EX-99.1
IMNN
Imunon Inc
8 May 24
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
8:15am
and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities
8-K
EX-99.1
IMNN
Imunon Inc
11 Apr 24
IMUNON Reports Compliance with Nasdaq Listing Requirements
9:00am
with Nasdaq listing requirements; unforeseen changes in the course of research and development activities and in clinical trials, including the fact
8-K
EX-99.1
IMNN
Imunon Inc
28 Mar 24
IMUNON Reports 2023 Financial Results and Provides Business Update
8:05am
million and $1.6 million in 2023 and 2022, respectively.
Research and development (R&D) expenses were $11.3 million for 2023, a decrease of $0.4 million … ) an impairment charge of $13.4 million due to the write off of In-Process Research & Development (IPR&D) assets and (ii) a non-cash gain of $5.4 million due
8-K
EX-99.1
99aa0wujqeafm l6kh
12 Mar 24
IMUNON Announces Leadership Change
5:05pm
8-K
EX-99.1
kbg4o1dfc
11 Dec 23
Departure of Directors or Certain Officers
8:35am
8-K
EX-99.1
ntujenq91kx6y91dmmwn
14 Nov 23
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.1
wp866cajcc
10 Aug 23
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
8:09am
8-K
EX-99.1
bpf4j5iec1ea
11 May 23
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
8:05am
CORRESP
h09d 2uall772xjq8
5 May 23
Correspondence with SEC
12:00am
UPLOAD
6z8ba23ffeknp2 18ul
3 May 23
Letter from SEC
12:00am